Improved Protease Partner Programs

        Pfizer

Catalyst signed a worldwide exclusive licensing agreement with Wyeth Pharmaceuticals, now a subsidiary of Pfizer, in June 2009.  Catalyst is responsible for discovery and research of novel FVIIa variants, including improved FVIIa proteases that may potentially allow their use in a prophylactic setting for hemophilia patients and for the control of bleeding in normal patients in a surgical or trauma setting.  Pfizer will be responsible for preclinical and clinical development, manufacturing and commercialization of resulting FVIIa products.

Alterase™ Therapeutics Partner Programs

       MedImmune

Catalyst Biosciences partnered with MedImmune in June 2009 to discover and develop Alterase™ Therapeutics targeting up to two undisclosed targets, one of which is implicated in inflammatory and autoimmune diseases.